At a glance
A dipeptide discussed in immune-cell and gene-expression research.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source describes experimental immune and tissue findings. Pulsed research schedules borrowed from related peptides require particular caution when interpreting their relevance.[1][2][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Vilon.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 20 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~6.67 mg/mL)
| Phase / Cycle | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Cycle 1, Day 1 | 67 mcg (0.067 mg) | 1 unit (0.01 mL) |
| Cycle 1, Day 2 | 133 mcg (0.133 mg) | 2 units (0.02 mL) |
| Cycle 1, Day 3 | 200 mcg (0.20 mg) | 3 units (0.03 mL) |
| Cycle 1, Day 4 | 267 mcg (0.267 mg) | 4 units (0.04 mL) |
| Cycle 1, Day 5 | 333 mcg (0.33 mg) | 5 units (0.05 mL) |
| Cycle 2+ (Days 1–5) | 333–667 mcg (0.33–0.67 mg) | 5–10 units (0.05–0.10 mL) |
Schedule: Inject once daily subcutaneously for 5 consecutive days, then rest for the remainder of a 4‑week cycle. Repeat monthly[4][5]. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the pulsed regimen.
- Goal: Support immune modulation and thymic function markers based on preclinical observations[1][2].
- Schedule: 5 consecutive days of subcutaneous injections per 4‑week cycle; repeat for 2–4 cycles.
- Dose Range: 67–667 mcg daily with gradual titration during the first cycle.
- Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate low‑volume measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested pulsed titration approach.
- Start: 67 mcg (1 unit) on Day 1; increase by ~67 mcg (1 unit) each day during first cycle.
- Target: 333–667 mcg (5–10 units) daily by Cycle 2 onward.
- Frequency: Once per day (subcutaneous) for 5 consecutive days per cycle[5].
- Cycle Length: 5 days on, ~23 days off (4‑week cycle); run 2–4 cycles.
- Timing: Any consistent time; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within ~1 week or aliquot and freeze[10].
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) short‑term or −80 °C (−112 °F) long‑term in dry, dark conditions; minimize moisture exposure[10].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~1 week or prepare aliquots and freeze to extend stability.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[9].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[7][8].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[9].
Materials & quantity planning
Source materials checklist · 20 mg
Plan based on an 8–16 week pulsed protocol (5 injection days per 4‑week cycle).
-
Peptide Vials (Vilon, 20 mg each):
- 8 weeks (2 cycles, 10 injections) ≈ 1 vial
- 12 weeks (3 cycles, 15 injections) ≈ 1 vial
- 16 weeks (4 cycles, 20 injections) ≈ 1 vial
-
Insulin Syringes (U‑100, 30‑ or 50‑unit preferred):
- Per cycle: 5 syringes (1/day × 5 days)
- 8 weeks: 10 syringes
- 12 weeks: 15 syringes
- 16 weeks: 20 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8–16 weeks (1 vial): 3 mL → 1 × 10 mL bottle
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per cycle: 10 swabs (2/day × 5 days)
- 8 weeks: 20 swabs
- 12 weeks: 30 swabs
- 16 weeks: 40 swabs → recommend 1 × 100‑count box
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 20 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 03
Research publication
Gavrisheva NA et al. (2005) — Effect of Vilon peptide on TGF‑β1 and vascular permeability in chronic renal failure (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
Kniaz’kin IA et al. (2002) — Effect of a peptide Vilon on immune aging (Adv Gerontol) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Research publication
Chernyak EY et al. (2000) — Synthetic dipeptide Vilon inhibits tumor growth and prolongs life in mice (Dokl Biol Sci) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Public health resource
MedlinePlus (NIH) — Subcutaneous (SQ) injections: patient information (opens in a new tab)medlineplus.gov
Back to overview ↑ - 10
Source document
Merck KGaA (Millipore Sigma) — Handling and storage guidelines for peptides and proteins (opens in a new tab)www.sigmaaldrich.com
Back to overview ↑ - 11
Public health resource
CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 12
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.